Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Software To Improve Clinical Trial Performance
TranSenda International, LLC announced today that it is developing a new solution, Cortex, designed to improve an organization"s ability to manage a clinical trial"s performance. Based upon patent-pending ClinBUS® data interchange technology already in use in TranSenda"s Office-Smart solutions, Cortex will enable organizations to leverage the power of access to centralized operational data from all applications used across all clinical studies. For years the industry has struggled with an increasingly fragmented environment of disconnected clinical applications, sites and partners. TranSenda"s Cortex, with its proven ClinBUS technology, represents a breakthrough in managing and controlling studies within a common environment-independent of study data formats and clinical trial applications.

New Data Proves Effectiveness Of Medtronic Insertable Cardiac Monitor In Detecting AF, Most Common Heart Rhythm Disorder
Atrial fibrillation (AF) is the most common arrhythmia, affecting an estimated 7 million people worldwide, including 4.5 million in the European Union1,2. Data presented today as a Hot Line session at the EUROPACE 2009 congress on the XPECT clinical trial, sponsored by Medtronic, Inc. (NYSE: MDT), shows that the Medtronic Reveal® XT Insertable Cardiac Monitor (ICM) reliably identifies patients with AF (sensitivity of 96.1 percent) and correctly confirms the absence of AF in patients (negative predictive value of 97.4 percent).
News of the day
Swine Flu And The Influenza Virus In 1918
The influenza virus that wreaked worldwide havoc in 1918-1919 founded a viral dynasty that persists to this day, according to scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. In an article published online on June 29 by the New England Journal of Medicine, authors Anthony S. Fauci, M.D., Jeffery K. Taubenberger, M.D., Ph.D., and David M. Morens, M.D., argue that we have lived in an influenza pandemic era since 1918, and they describe how the novel 2009 H1N1 virus now circling the globe is yet another manifestation of this enduring viral family.
Diagnostics

Medtronic And Abbott Laboratories Resolve Global Vascular Patent Disputes

Medtronic, Inc. (NYSE: MDT) announced global resolution of all outstanding intellectual property litigation with Abbott Laboratories. Terms of the agreement stipulate that neither party will sue each other in the field of coronary stent and stent delivery systems for a period of at least 10 years, subject to certain conditions. The agreement includes a $400 million settlement payment to be made to Abbott and also results in a $42 million success payment to evYsio Medical Devices, LLC, as part of a Medtronic sublicense to Abbott of the evYsio stent design technology. In connection with the settlement, Medtronic expects to report in its first quarter financial results a special charge to be calculated in accordance with generally accepted accounting principles. Following the resolution of these disputes with Abbott, Medtronic has now resolved or settled substantially all intellectual property litigation affecting the stent design and stent delivery systems of its bare metal and drug-eluting stent franchise. As a result, Medtronic will now focus more res on efforts to improve health care for patients with vascular disease. Medtronic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009